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Abstract
In the management of women diagnosed with endometrial hyperplasia (EH), it is crucial to determine the risk of coexistent
cancer. Diabetes mellitus has been recently suggested as a significant risk factor. However, results in this regard are conflicting.
Our aim was to assess the association between diabetes mellitus and coexistent cancer in women diagnosed with endometrial
hyperplasia. A systematic review and meta-analysis was performed by searching electronic databases from their inception to
October 2018 for studies assessing the presence of coexistent cancer after a preoperative diagnosis of endometrial hyperplasia in
women stratified for diabetes mellitus. Odds ratio was calculated with 95% confidence interval; a p value <0.05 was considered
significant. Twelve retrospective studies with 1579 EH were included. Diabetes mellitus showed significant association with the
presence of cancer coexistent with endometrial hyperplasia (OR = 1.96; 95% CI, 1.07–3.60; p = 0.03). Heterogeneity among
studies was moderate (I2 = 55%). Funnel plot showed asymmetric distribution of OR values, with the large and accurate studies
showing results stronger than small and less accurate one; this finding should exclude a publication bias. In women diagnosed
with endometrial hyperplasia, diabetes mellitus is a risk factor for coexistent cancer, and thus may be included in a predictive
algorithm for the risk stratification. In women conservatively treated, glycemic control may be required to prevent the risk of
progression. Further studies are necessary to confirm the clinical significance of diabetes mellitus in this field.
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Introduction
Endometrial hyperplasia (EH) is an irregular proliferation of
endometrial glands with a gland to stroma ratio higher than the
normal endometrium in the proliferative phase [1].
EH can precede or coexist with endometrial cancer (EC),
endometrioid type (Btype I^ EC in the Bokhman classifica-
tion) [1, 2]. Histological studies of EH have focused on the
definition of the characteristics that correlate with higher risk
of EC [2]. The main morphologic factors associated with the
risk of cancer are cytologic atypia, glandular crowding and
appearance different from adjacent endometrium [2–4].
However, histomorphologic features have shown low repro-
ducibility among pathologists [5], and several problems may
affect the diagnosis on biopsy specimens, such as tissue inad-
equacy or artifact changes [6].
Molecular features of EH may also be useful to recognize
precancerous lesions; in particular, aberrant expression of
markers involved in endometrial carcinogenesis may be stud-
ied by immunohistochemistry in EH specimens [2, 7–10].
Given that also clinical data may impact on the risk of EC,
several authors tried to elaborate an algorithm to predict of
cancer in EH [11–13]. Nonetheless, a reliable predictive mod-
el has never been achieved, in particular because data in this
field are conflicting, and the actual relevance of certain param-
eters is undefined.
In recent years, diabetes mellitus has been proposed as a
factor independently associated with the risk of coexistent EC
in patients diagnosed with EH on endometrial biopsy [13].
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Objective of our study was to assess if diabetes mellitus is a
risk factor for coexistent cancer in EH. We aimed to define
whether or not diabetes mellitus should be considered in the
preoperative assessment of EH.
Materials and Methods
Methods for collection, extraction and analysis of data, and for
risk of bias assessment, were defined a priori. Three authors
(AR, AT, GS) independently performed all review stages, and
disagreements were resolved by discussion with a fourth au-
thor (MM).
This study was reported following the Preferred Reporting
Item for Systematic Reviews and Meta-analyses (PRISMA)
statement [14].
Search Strategy
MEDLINE, EMBASE, Web of Sciences, Scopus,
ClinicalTrial.gov, Cochrane Library, OVID, and Google
Scholar were searched for relevant articles from the
inception of each database to October 2018. Several
different combinations of the following text words were
used: Bendometrial hyperplasia^; Bendometrial intraepithelial
neoplasia^; BEIN^; Bdiabetes^; Bcancer^; Bcarcinoma^;
Badenocarc inoma^; Bendometr ioid^; Bprecancer^;
Bpremalignant^; Bprecursor^; Bcoexistent^; Bconcurrent^;
Boccu l t^; Bbiopsy^; Bsampl ing^; Bpreopera t ive^;
Bhysterectomy .^ All relevant references were also reviewed.
Study Selection
We included all peer-reviewed retrospective or prospective
studies meeting the following inclusion criteria:
& sample constituted by women diagnosed with EH and
who underwent hysterectomy;
& assessment of the presence of EC on histologic examina-
tion of hysterectomy specimen;
& assessment of the association between diabetes mellitus
and presence of EC on hysterectomy.
Exclusion criteria, defined a priori, were:
& data not extractable;
& case reports and reviews;
& overlapping patient data with a study already included.
Assessment of Risk of Bias among Studies
The Methodological Index for NOn-Randomized Studies
(MINORS) was used to assess the risk of bias among the
included studies [15]. Five domains related to the risk of bias
were considered applicable to the included studies: 1) Aim
(i.e. clearly stated aim); 2) Inclusion of consecutive patients
(i.e. inclusion of all eligible patients in the period of study); 3)
Endpoints appropriate to the aim (i.e. unambiguous explana-
tion of the criteria used to measure outcomes); 4) Unbiased
assessment of endpoints (i.e. unbiased assessment of the study
endpoints); 5) Follow-up period appropriate to the aim (i.e. if
the time interval between index biopsy and hysterectomy was
<1 year; in fact, only EC diagnosed within 1 year from EH
diagnosis are accepted as Bcoexistent^ cancers in the literature
[16, 17]).
Review authors’ judgments were categorized as Blow risk
of bias^, Bhigh risk of bias^ or Bunclear risk^ of bias if data
about the domain were Breported and adequate^, Breported but
inadequate^ and Bnot reported^, respectively.
Data Extraction and Analysis
Data were extracted from eligible studies without modifica-
tion. Two by two contingency tables were prepared for each
study, reporting two dichotomous qualitative variables: pres-
ence of diabetes mellitus and presence of cancer on the sub-
sequent hysterectomy.
Diabetes mellitus was defined as hemoglobin A1c level of
6.5% or greater, a fasting plasma glucose level of 126 mg/dL
or greater, or a 2-h plasma glucose level of 200 mg/dL or
greater [18].
Odds ratio (OR) was calculated for each study and as
pooled estimate with 95% confidence interval (CI).
Statistical heterogeneity among studies was quantified by
using the inconsistency index (I2): heterogeneity was consid-
ered insignificant for I2 < 25%, low for I2 < 50%, moderate for
I2 < 75% and high for I2 ≥ 75%. In case of I2 < 50%, the fixed
effect model of Mantel-Haenszel was used; otherwise, a ran-
dom effect model was used. Results were reported graphically
on a forest plot.
The risk of bias across studies (publication bias) was
assessed by reporting OR on x axis and standard error on y
axis on a funnel plot; asymmetry of funnel plot suggests pub-
lication bias if little accurate studies (high standard error) have
stronger results (higher OR) than more accurate ones.
The data analysis was performed using Review Manager
5.3 (Copenhagen: The Nordic Cochrane Centre, Cochrane
Collaboration, 2014).
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Results
Selection and Characteristics of the Studies
Twelve retrospective studies, assessing a total sample of 1579
women diagnosed with EH, were included [11–13, 19–27].
Details about the whole process of study selection are shown
in Fig. 1.
Sampling methods included curettage, pipelle biopsy, hys-
teroscopic biopsy and hysteroscopic resection.
Details about characteristics of the included studies are
shown in Table 1.
Assessment of Risk of Bias among Studies
For the BAim^, BEndpoints appropriate to the aim^ and
BUnbiased assessment of endpoints^ domains, no particular
sources of bias were found. Therefore, all studies were con-
sidered at low risk of bias.
For the BInclusion of consecutive patients^ domain, 3 stud-
ies were considered at low risk of bias, since they clearly
stated that patients were selected consecutively; the other 11
studies reported inclusion criteria and period of enrollment,
but it was unclear whether all patients were selected, hence
the unclear risk of bias.
For the BFollow-up period appropriate to the aim^ domain,
5 studies were considered at low risk, since they specified that
all patients underwent hysterectomy within 1 year from the
index diagnosis. Six studies only stated that all biopsies were
in the preoperative phase, or reported the mean/median inter-
val, and thus they were considered at unclear risk. One study
was considered at high risk, because some patients had an
index biopsy-to-hysterectomy interval > 1 year.
Results of risk of bias assessment are shown in Fig. 2.
Meta-Analysis
Diabetes mellitus showed significant association with the
presence of cancer coexistent with EH (OR = 1.96; 95% CI,
1.07–3.60; p = 0.03). There was moderate heterogeneity
among studies (I2 = 55%) (Fig. 3).
Funnel plot showed asymmetric distribution of OR values,
with the large and accurate studies showing results stronger
than small and less accurate one; this finding should exclude
the possibility of a publication bias (Fig. 4).
Discussion
Our study showed that, in women diagnosed with EH, diabe-
tes mellitus was significantly associated with the risk of coex-
istent cancer. To the best of our knowledge, this is the first
systematic review and meta-analysis assessing the association
between diabetes mellitus and coexistent EC in EH.
The stratification of the risk of EC in EH is a long-standing
issue. Several histologic classifications had been proposed,
such as Bmild^, Bmoderate^ and Bsevere^, or Bcystic
glandular^, Badenomatous^ and Badenomatous atypical^, or
Bsimple^, Bcomplex^ and atypical^ [2, 28–30]. The 2014
WHO classification indicates cytologic atypia as the crucial
feature for differentiating precancerous EH from benign EH
[1]. On the other hand, the endometrial intraepithelial neopla-
sia (EIN) classification proposes a combination of 3 morpho-
logical features (glandular crowing, lesion size >1 mm, cytol-
ogy different from adjacent endometrium) [3, 4, 30]. None of
these features perfectly reflects the risk of cancer, but they
may show different values of sensitivity and specificity [3].
Based on this finding, a novel integration of both classification
systems has been recently proposed in order to better stratify
the risk of coexistent EC. Such novel classification separates
EH into three histologic categories: benign EH, EIN without
cytologic atypia (at lower risk) and EIN with cytologic atypia
(at higher risk) [3, 29]. Unfortunately, the inter- and intra-
observer reproducibility of histologic examination is subopti-
mal [5].
Several molecular and immunohistochemical markers have
been also studied to identify precancerous EH, but none ap-
peared reliable as a stand-alone marker [2, 7–9]. In particular,
PTEN, the key molecule in endometrial carcinogenesis, has
shown low diagnostic accuracy in the differential diagnosis
between benign and precancerous EH [9, 31].
Fig. 1 Flow diagram of studies identified in the systematic review
(Prisma template [Preferred Reporting Item for Systematic Reviews and
Meta-analyses])
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Regarding clinical factors, some factors involved in the
absolute risk of EC, such as BMI, age and parity, might have
a prognostic significance for the risk of coexistent EC in EH
[11–13, 19–27].
In our study, we focused on diabetes mellitus. The rela-
tionship between diabetes mellitus and EC is controversial.
In fact, some authors advocate the importance of diabetes
mellitus as a risk factor for EC, while other ones suggest
that such association was not independent, but it was af-
fected by BMI, as obesity correlates to insulin-resistance
[32, 33]. A recent umbrella review concluded that, unlike
BMI, further evidence is necessary regarding the associa-
tion between diabetes mellitus and EC [32].
In the 2015, Matsuo et al. performed a case-control
study, searching for factors associated with the risk of co-
existent cancer in 211 women preoperatively diagnosed
with EH. They found that the presence of complex atypical
EH, older age, obesity and diabetes mellitus were risk fac-
tors for coexistent EC. The significance of diabetes
mellitus was subsequently confirmed at the multivariate
Fig. 2 a Assessment of risk of
bias. Summary of risk of bias for
each study; Plus sign: low risk of
bias; minus sign: high risk of bias;
question mark: unclear risk of
bias. b Risk of bias graph about
each risk of bias item presented as
percentages across all included
studies
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analysis, demonstrating its independence from obesity
[13].
In our current study, we found that diabetes mellitus was
significantly associated with the risk of EC coexistent with
EH.
Diabetes mellitus, in particular type II, is characterized by a
hyperinsulinic state, which leads to an increase in the available
circulating levels of insulin like growth factor 1 (IGF-1), fa-
voring the activation of pro-proliferative kinase pathways
[34]. The activation of these pathways might promote the
progression form EH to EC.
Our findings are consistent with the results from a recent
meta-analysis, which showed that diabetes mellitus was asso-
ciated with the risk of EC coexistent with endometrial polyps
[35].
Diabetes mellitus may be a major non-histologic and non-
molecular factor which affects the risk of progression of EH to
EC. To date, management of patients with EH is mainly based
on histological features of EH, and cytologic atypia is the most
important parameter. In fact, while non-atypical EH may be
managed by observation alone, atypical EH requires total hys-
terectomy, with conservative approaches (e.g. oral progestins,
medicated intrauterine device, hysteroscopic resection) re-
served to selected cases [36–39]. Diabetes mellitus may be
integrated in a predictive algorithm for the risk of coexistent
EC, together with other clinical, histomorphologic and immu-
nohistochemical parameters, in order to achieve a more tai-
lored management of the patients. Women with EH at higher
risk for ECmay have a higher surgical priority if hysterectomy
is chosen, or they may require a closer and more careful
follow-up in case of conservative treatment (every 3 months
rather than 3–6 months, as actually recommended [36]).
Furthermore, in women conservatively treated, an adequate
glycemic control may be necessary to reduce the risk of pro-
gression to cancer. In this regard, it has been proposed that
metformin, a major anti-diabetic drug, may be useful in the
conservative treatment of EH [40]. It would be interesting to
assess how diabetes mellitus may affect the outcome of the
conservative treatment of EH, as molecular markers appear
inadequate to predict the outcome [41–43]. However, in our
previous study we found that diabetes mellitus did not seem to
significantly affect the responsiveness of EH to progestins
[44].
A limitation to our results may lie in the retrospec-
tive design of the included studies; such a limitation
may be tempered by the inclusion of consecutive
patients.
Our results might be affected by a significant heterogeneity
among studies. However, according to the funnel plot, small
and heterogeneous studies showed lower OR values com-
pared to the larger and more homogeneous studies. This
Fig. 3 Forest plot reporting odds ratio (OR) of individual studies and as pooled estimate, with 95% confidence interval (CI), for the risk of coexistent
cancer in diabetic women with endometrial hyperplasia vs non-diabetic ones
Fig. 4 Funnel plot for the assessment of the risk of bias across studies
(publication bias). Odds ratio (OR) values are reported on the x axis and
standard error (SE) values on the y axis
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finding indicates not only that publication bias is not present,
but also that the actual association between diabetes mellitus
and risk of coexistent cancer may be higher.
Further studies are necessary to confirm the prognostic rel-
evance of diabetes mellitus in women diagnosed with EH and
its usefulness in the patient management.
Conclusion
Diabetes mellitus in women diagnosed with EH appears as a
risk factor for coexistent EC. Diabetes mellitus might be in-
cluded in a predictive algorithm for the risk of EC in EH,
together with other clinical, histologic and immunohistochem-
ical data, in order to tailor the management of patients with
EH. An adequate glycemic control might be required in wom-
en with EH in order to reduce the risk of imminent
progression.
Further studies are necessary to confirm the clinical appli-
cability of diabetes mellitus in the risk stratification of EH.
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